We read with great interest the recent Breast Cancer Research paper by Desrichard and colleagues [1] reporting the association between CHEK2 mutations and non-BRCA hereditary breast cancer risk. Th is report summarized the results of diff erent case-control studies to provide an overview of CHEK2 1100delC mutation and susceptibility to early-onset breast cancer (EOBC) and bilateral breast cancer (BBC). We believe there are signifi cant issues to note regarding the authors' study.
as that of Desrichard and colleagues, we located three relevant case-control studies in PubMed comprising a total of 3,742 EOBC cases and 8,405 controls [6] [7] [8] , which were not included in the pooled analy ses. Furthermore, we have combined all of the studies on European populations into a new pooled analysis. By using a fi xedeff ect model, signifi cant associations were found to be associated with CHEK2 1100delC mutation in patients with EOBC (odds ratio 3.14, 95% confi dence interval 1.86 to 5.28).
In conclusion, the association between CHEK2 1100delC mutation and BBC risk may be complex, and further studies will likely be needed to clarify the correlation of BBC and familial breast cancer charac teristics. Similarly, further studies on EOBC-specifi c populations would be helpful for the purpose of better evaluating the association between CHEK2 1100delC mutation and EOBC risk.
Abbreviations BBC, bilateral breast cancer; EOBC, early-onset breast cancer.
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